Indian Institute of Technology Bombay

About: Indian Institute of Technology Bombay is a education organization based out in Mumbai, India. It is known for research contribution in the topics: Catalysis & Computer science. The organization has 16756 authors who have published 33588 publications receiving 570559 citations.

Trigger responsive polymeric nanocarriers for cancer therapy

Abstract: Conventional chemotherapy for the treatment of cancer has limited specificity when administered systemically and is often associated with toxicity issues. Enhanced accumulation of polymeric nanocarriers at a tumor site may be achieved by passive and active targeting. Incorporation of trigger responsiveness into these polymeric nanocarriers improves the anticancer efficacy of such systems by modulating the release of the drug according to the tumor environment. Triggers used for tumor targeting include internal triggers such as pH, redox and enzymes and external triggers such as temperature, magnetic field, ultrasound and light. While internal triggers are specific cues of the tumor microenvironment, external triggers are those which are applied externally to control the release. This review highlights the various strategies employed for the preparation of such trigger responsive polymeric nanocarriers for cancer therapy and provides an overview of the state of the art in this field.

Dendrimer–Doxorubicin conjugate for enhanced therapeutic effects for cancer

Abstract: An oligo(ethylene glycol)- grafted amidoamine dendrimer was synthesized and characterized by FTIR, MS, 1H and 13C NMR. The dendritic scaffold was evaluated for its potential to load doxorubicin and its release, thereafter. The interaction between drug and the dendrimer was reviewed by ζ potential, HPLC, NMR and FTIR spectroscopy. The drug encapsulation efficiency was as high as 52%. The temperature stimulated release characteristics of the DOX loaded dendrimers were studied in PBS and SBF at 37 °C (physiological temperature) and 43 °C (hyperthermic temperature). A biphasic suspension of the dendrimer–drug conjugate and a magnetic fluid entitles release of the drug under AC magnetic field which can simultaneously be used for hyperthermia treatment of cancer. The efficacy of dendrimer–DOX conjugate was evaluated in vitro against cancer cell lines and the IC50 was estimated.